Data Show Efficacy of Secukinumab in Multiple Aspects of Ankylosing Spondylitis After 5 Years

At the annual meeting, researchers led by Xenofon Baraliakos, MD, of the Ruhr-University of Bochum in Germany, presented long-term, end-of-study findings from the phase III MEASURE 1 extension trial, which is evaluating the safety and efficacy of secukinumab (SEC) in patients with ankylosing spondylitis (AS).

Research Shows Secukinumab Is Effective in the Long Term Against Signs and Symptoms of...

At the annual meeting, a group of researchers led by Iain B. McInnes, MBChB, MRCP, PhD, of the University of Glasgow in the United Kingdom, presented long-term data from a phase III study evaluating the safety and efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA).

Questions to Consider When Collecting Patient-Generated Data

Prior to the start of the annual meeting, an afternoon of presentations focused on “Applications of Mobile Health Technologies.”

The PROMIS of Measuring Patient-Reported Outcomes

A pre-meeting session at the annual meeting delved into the benefits and challenges of “PROMIS Versus Legacy Data Instruments” in collecting patient-reported outcomes (PROs) in rheumatology.

De-Hyping Artificial Intelligence and Machine Learning in Health Care

Prior to the annual meeting, the ACR Clinical Research Conference focused on technology advances that are changing the landscape of medicine and rheumatology. Beyond electronic health records, there is a broad range of digital and mobile technologies.

Making Medication Adherence “the Fifth Vital Sign”

During an afternoon of specialized pre-meeting sessions at the annual meeting, speakers addressed various aspects of health technology. One presenter, Bernard Vrijens, PhD, of AARDEX Group, stressed to attendees that “Medication Adherence Is a Key Element to Integrate in e-Health.”